News As Trump visits UK, GSK pledges $30bn in US investment GSK's investment drive includes a new facility in Pennsylvania, and follows some high-profile abandoned projects by drugmakers in the UK.
News AZ's bid for Fasenra approval in COPD falls short AstraZeneca has abandoned Fasenra development in COPD, but there is better news for the company with a new version of lupus drug Saphnelo.
News Flood of warning letters follows DTC ad clampdown The FDA has lost no time following through on its plan to tighten up DTC advertising of medicines, sending out dozens of untitled and warning letters.
News Imfinzi becomes first NHS drug for aggressive lung cancer AstraZeneca's PD-L1 inhibitor Imfinzi is the first drug therapy to be recommended for routine NHS use in limited-stage small cell lung cancer.
News FDA's Makary explains 'overdue' pharma ads crackdown FDA Commissioner Marty Makary has called DTC ads for medicines a "public health crisis" as the industry prepares for a regulatory crackdown.
News RFK Jr expands ACIP ahead of highly anticipated meeting Five members have been added to a controversial CDC vaccines panel ahead of a meeting this week that could have an impact on US immunisation policy.
Patients Making direct-to-patient work, with Matt Wadyka Matt Wadyka, chief client strategy officer at Inizio Medical, spoke to pharmaphorum about the ins and outs of direct-to-patient programmes in pharma.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.